Tokuyama (4043) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
5 Jun, 2025Executive summary
Net sales for Q3 FY2024 rose 1.3% year-over-year to ¥253.3B, driven by strong semiconductor-related and dental materials sales.
Operating profit increased 24.4% to ¥21.0B, mainly due to cost improvements and lower coal prices.
Profit attributable to owners of parent surged 42.1% year-over-year to ¥16.9B, aided by extraordinary gains from investment security sales and business restructuring.
Advanced fields, especially semiconductors, exceeded initial forecasts, but chemicals and cement sales trends led to a downward revision of previous forecasts.
Comprehensive income for Q3 FY2024 was ¥15.5B, down 7.4% year-over-year due to negative other comprehensive income.
Financial highlights
Q3 FY2024 net sales: ¥253.3B (+1% YoY); operating profit: ¥21.0B (+24% YoY); ordinary profit: ¥21.9B (+29% YoY); net income: ¥16.9B (+42% YoY); EPS: ¥235.15.
Total assets as of Dec 31, 2024: ¥477.4B (+4.4% from Mar 31, 2024); shareholders' equity: ¥257.2B; net assets: ¥270.1B.
Interest-bearing debt increased to ¥110.9B due to bond issuance.
Cost of sales decreased 2.1% YoY, while SG&A expenses rose 5.0% due to higher R&D and logistics costs.
Cash and cash equivalents at ¥69.0B, with ample liquidity.
Outlook and guidance
FY2024 net sales forecast revised to ¥348.0B (up 1.8% YoY), operating profit to ¥31.0B (up 20.9%), and profit attributable to owners of parent to ¥25.0B (up 40.8%).
Electronic & Advanced Materials segment forecast raised, while Chemicals and Cement forecasts lowered.
Full-year EPS forecast essentially unchanged at ¥347.49; dividend forecast raised to ¥100 per share.
Guidance subject to change based on market and operational factors.
Latest events from Tokuyama
- Operating profit surged on strong semiconductor sales and acquisitions, despite lower revenue.4043
Q3 202630 Jan 2026 - Operating profit up 37.2% on cost improvements and semiconductor demand; major acquisition completed.4043
Q2 202629 Oct 2025 - Operating profit rose 5.1% despite lower sales, driven by cost improvements and semiconductor demand.4043
Q1 202629 Jul 2025 - Operating and net profit soared on cost cuts and semiconductor demand, with outlook steady.4043
Q2 202513 Jun 2025 - Operating profit and net income surged despite lower revenue, with guidance unchanged.4043
Q1 202513 Jun 2025 - Profits and sales are set to reach record highs, with a major healthcare acquisition ahead.4043
Q4 20256 Jun 2025